GreinIPintoNLoboA, et al.
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study. Lupus2020;
29: 934–942.
2.
MokCCHoLYFongLSToCH.Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.Ann Rheum Dis2013;
72: 659–664.
3.
ExleyCSiesjöPErikssonH.The immunobiology of aluminium adjuvants: how do they really work?Trends Immunol2010;
31: 103–109.
4.
PerriconeCColafrancescoSMazorRDSorianoAAgmon-LevinNShoenfeldY.Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects.J Autoimmun2013;
47: 1–16.
5.
GuimarãesLEBakerBPerriconeCShoenfeldY.Vaccines, adjuvants and autoimmunity.Pharmacol Res2015;
100: 190–209.
6.
GattoMAgmon-LevinNSorianoA, et al.
Human papillomavirus vaccine and systemic lupus erythematosus.Clin Rheumatol2013;
32: 1301–1307.
7.
ItoHNodaKHiraiKUkichiTFuruyaKKurosakaD. [
A case of systemic lupus erythematosus (SLE) following Human papillomavirus (HPV) vaccination]. Nihon Rinsho Meneki Gakkai Kaishi2016;
39: 145–149.
8.
SegalYDahanSCalabròMKanducDShoenfeldY.HPV and systemic lupus erythematosus: a mosaic of potential crossreactions.Immunol Res2017;
65: 564–571.
9.
NataleCGianniniTLuccheseAKanducD.Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences.Immunol Cell Biol2000;
78: 580–585.
10.
KanducDStufanoALuccheseGKusalikA.Massive peptide sharing between viral and human proteomes.Peptides2008;
29: 1755–1766.
